<DOC>
	<DOCNO>NCT00421148</DOCNO>
	<brief_summary>The purpose study : - explore dose-response relation sugammadex give reversal agent reappearance T2 0.6 mg.kg-1 rocuronium pediatric adult subject - explore pharmacokinetics sugammadex pediatric adult subject , evaluate safety sugammadex pediatric adult subject .</brief_summary>
	<brief_title>Dose-Finding Pediatric Trial With Sugammadex ( 19.4.306 ) ( P05961 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<criteria>ASA class 1 2 , age 28 day 65 year inclusive , age 2 65 year inclusive Germany age 6 65 year inclusive Finland Scheduled general anesthesia anticipate duration anesthesia least 60 minute , without need muscle relaxation one single dose 0.6 mg.kg1 rocuronium Scheduled surgical procedure supine position Subjects , and/or whose parent ( ) legal guardian ( ) give write informed consent [ appropriate assent , applicable ] Known suspect neuromuscular disorder impair NMB and/or significant renal dysfunction , Germany creatinine blood urea nitrogen outside local reference range Known suspected ( family ) history malignant hyperthermia Known suspect allergy narcotic , muscle relaxant medication use general anesthesia Use medication expect interfere rocuronium give trial , base dose time administration Pregnancy Childbearing potential use follow method birth control : condom diaphragm spermicide , vasectomized partner ( &gt; 6 month ) , IUD , abstinence Breast feeding Prior participation trial 19.4.306 Participation another clinical trial , preapproved NV Organon , within 30 day enter trial 19.4.306</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>